Advanced Search


Study ID Status Title Patient Level Data
SAM30020 Completed Efficacy and tolerability of the salmeterol/fluticasone 50/100 mcg combination Diskus, inhaled once daily in the evening, in comparison to the p.r.n. inhalation from the reproterol/sodium cromoglycate 0.5/ 1 mg combination MDI, as initial therapy for patients with mild asthma – a multicentre, ra ...
SAM30021 Completed A multi-centre, randomised, open-label, parallel group clinical trial to assess the efficacy and safety of Salmeterol/Fluticasone Propionate combination product (2x 25/125mg/actuation, bd) via a hydrofluoroalkane metered-doseinhaler compared…
SAM30022 Completed A phase IV, multi-centre, double-blind, double-dummy, parallel group, randomised study comparing Seretide (25/50 2 puffs bd) via the Evohaler (MDI-HFA) with Beclometasone dipropionate (200mcg 2 puffs bd) via the MDI-CFC in adolescents and adults experiencing moderate symptoms of reversible airwa ...
SAM3802 Completed An observational study to assess the health related quality of life impact of treating poorly controlled asthmatic children with Seretide 50/100mcg
SAM40004 Completed A multi-centre, randomised, double-blind, placebo-controlled parallel group study to compare the effect on airway inflammation and remodeling of treatment with salmeterol/fluticasone propionate combination product (50/100mg strength) bd via the Accuhaler inhaler, or fluticasone propionate…
SAM40008 Completed A Multicentre, Randomised, Double-Blind, Parallel Group Comparison of the Efficacy of SERETIDE* bd and Fluticasone Propionate bd (Both Via DISKUS*/ACCUHALER*, Inhaler) when Tapering the Inhaled Corticosteroid Dose in Asthmatic Adults Study Listed on
SAM40010 Completed A randomised, double blind, double-dummy, parallel-group, twelve week comparison of salmeterol/fluticasone propionate (FP) DISKUS/ACCUHALER 50/100mcg bd. with budesonide 200mcg bd. plus formoterol 4.5mcg bd. (both via breath-actuated dry powder inhaler [BADPI]) in Adult and Adolescent Asthmatics.
SAM40012 Completed A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate (SFC) 50/100mcg strength) bd via DISKUS/ACCUHALER inhaler, 2) fluticasone propionate 200mcg bd via DISKUS/ACCUHALER inhaler, 3) fluticasone propionate 100mcg bd via DISKUS/ACCUHALER inhaler in children aged 4- 11 years with asthma Study Listed on
SAM40023 Completed A 6 week randomized, double-blind, parallel group study to compare efficacy of fluticasone propionate 250mcg BID, salmeterol 50mcg BID and fluticasone propionate 250mcg plus salmeterol 50 mcg BID for the treatment of nocturnal airway obstruction.
SAM40027 Completed A Multicentre, stratified, randomised, double-blind, parallel-group, step-up comparison of the level of asthma control achieved with salmeterol/fluticasone propionate combination diskus (Accuhaler) dry powder inhaler compared with fluticasone propionate Diskus alone in adults and adolescents. Study Listed on
SAM40030 Completed A phase IV, multicentre, randomised, double blind, single dummy, parallel group study to compare the anti-inflammatory action of Seretide 50/100 bd via MDI with Flixotide 100mg bd via MDI plus montelukast 10mg od for 12 weeks in adults with mild to moderate asthma who are currently taking…
SAM40031 Completed A 13 month, randomised, double-blind, parallel-group comparison of the efficacy of Seretide and Flixotide(fluticasone propionate Accuhaler) when down-titrating the inhaled corticosteroid dose in asthmatic adults who have previously received SeretideTM 500/50 mg twice daily for at least 4 weeks. Study Listed on
SAM40032 Completed A multi-centre, open label study to demonstrate the efficacy and tolerability of Seretide Accuhaler 50/100, 50/250 or 50/500mg twice daily after substituting for budesonide or beclomethasone dipropionate in doses of 500mg up to 2000mg daily in subjects with reversible airways obstruction.
SAM40034 Completed A double-blind, randomised, parallel group, 12-week comparison of fluticasone propionate/salmeterol combination Diskus 100/50mcg BID with fluticasone propionate (FP) 250mcg BID as initial maintenance treatment in persistent asthma (Seretide Nordic Jump-Up Study)
SAM40036 Completed A 12-week multicentre, randomised, double-blind, double-dummy, parallel group study to compare the efficacy and tolerability of once daily salmeterol/fluticasone propionate combination (salm/FP) 50/100mcg at night via the DISKUS/ACCUHALER with once daily budesonide (BUD) 400mcg at night via a breath-actuated dry powder inhaler (BADPI) as initial maintenance therapy in mild-to-moderate asthmatic subjects Study Listed on
SAM40040 Completed A 24-week, randomsed, double dummy, double blind, parallel group study to compare the occurence of exacerbations between Seretide Diskus 50/250 bd and Symbicort BADPI (Turbuhaler) 4.5/160 two inhalations bd in subjects with moderate to severe asthma Study Listed on
SAM40042 Completed A double-blind, double-dummy, randomised, cross-over study to compare the bronchodilating action of Seretide Accuhaler 50/100mcg and Symbicort breath-actuated dry powder inhaler 6/200mcg in subjects with asthma after a single dose before and after 4 weeks of treatment Study Listed on
SAM40047 Completed Duration of action of single inhalations of the salmeterol/ fluticasone combination product (50/250 µg) in comparison with the formoterol/ budesonide combination product (4.5/160 µg) in patients with moderate asthma - a randomised, double-blind, double-dummy, cross over study.
SAM40048 Completed Randomised, double-blind, parallel group study on the efficacy and tolerability of the salmeterol 50 mcg / fluticasone 250 mcg combination Diskus compared to the formoterol 6 mcg / budesonide 200 mcg combination turbohaler administered twice daily in patients with moderate bronchial asthma.
SAM40049 Completed A Danish, multi-centre, comparative, parallel-group study to determine whether initiation of combination treatment with Seretide™ 50/100 mg bd offers better asthma control than monotherapy with Flixotide™ 100 mg bd to adult asthmatic subjects uncontrolled on short-acting bronchodilator alone.
SAM40056 Completed Randomised, double-blind, double-dummy, 52-week, parallel group study of a standard dosing regimen with salmeterol/fluticasone propionate50/250 twice daily Diskus versus a symptom-driven, variable dosing regimen with formoterol/budesonide combination 4.5/160 in adult asthmatics Study Listed on
SAM40058 Completed A double-blind, randomised, parallel group study to evaluate the safety and tolerability of administering two inhalations twice daily of the salmeterol/fluticasone propionate combination (SERETIDE) in subjects with asthma over two weeks. Study Listed on
SAM40062 Completed A single-centre, single-dose, double-blind, double-dummy, placebo-controlled, randomised, three-way crossoverstudy to compare the duration of action of SERETIDE* DISKUS* 50/100mcg versus formoterol/budesonidecombination 4.5/160mcg Breath-Actuated Dry Powder Inhaler (BADPI) in subjects with asthma Study Listed on
SAM40065 Completed A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/sameterol DISKUS twice daily or fluticasone propionate DISKUS twice daily (or placebo twice daily if asymptomatic) Study Listed on
SAM40066 Completed A Muticenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day versus Montelukast 10mg every day in Adolescent and Adult subjects with Asthma and Seasonal allergic rhinitis who are Receiving Concurrent Open-Label Advair Diskus 100/50mcg twice daily Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.